Unmet challenges in high risk hematological malignancies: from benchside to clinical practice

Turin, September 13-14, 2018

THURSDAY SEPTEMBER 13, 2018

R. Chen

The evolving role of immunotherapy in lymphomas

Hodgkin Lymphoma and T-cell Lymphoma

Chairmen: P. Corradini, U. Ricardi

H. Stein

Histopathological and biological characterization of high risk Hodgkin Lymphoma

S.A. Pileri

Histopathology and molecular biology of T-cell Lymphoma

F.A. D’Amore

How I treat high risk T-cell Lymphomas

Mantle Cell Lymphoma

Chairmen: M. Spina, C. Visco

O. Hermine

How I treat high risk Mantle Cell Lymphoma in rst line

G. Hess

How I treat relapsed/refractory Mantle Cell Lymphoma

High Risk Aggressive Lymphoma

Chairmen: M. Martelli, U. Vitolo

G. Lenz

Biological identi cation of high risk DLBCL

G. Nowakowski

How I treat high risk DLBCL in rst line

A. Chiappella

How I treat DLBCL in relapse

A.J.M. Ferreri

How I treat high risk extranodal DLBCL

Chronic Lymphocitic Leukemia and Indolent Lymphoma

Chairmen: M. Ladetto, G. Rossi

G. Gaidano

Biology of high risk CLL

F. Bosch

How I treat high risk CLL

A. Zamò

Biological de nition of high risk FL

M. Ghielmini

How I treat high risk FL

FRIDAY SEPTEMBER 14, 2018

Multiple Myeloma and Waldenström Macroglobulinemia

Chairmen: M. Boccadoro, M. Massaia

N. Giuliani

Biology of high risk Multiple Myeloma

A. Larocca

How I treat elderly high risk Multiple Myeloma

C. Buske

How I treat high risk Waldenström Macroglobulinemia

S. Schuster

CAR-T cell therapy pros and contras

Myeloproliferative Disorders

Chairmen: E. Angelucci, A.M. Carella

N. Gangat

Biology of high risk myeloproliferative disorders

P. Pregno

How I treat high risk CML

F. Passamonti

How I treat high risk myeloproliferative neoplasm

Acute Lymphoblastic Leukemia

Chairmen: R. Cairoli, A. Rambaldi

J. Trka

Biology of high risk ALL

R. Bassan

How I treat high risk ALL in rst line

F. Ferrara/ F. Pane

How I treat relapsed/refractory AL

Acute Myeloblastic Leukemia and Myelodisplastic Syndrome

Chairmen: F. Pane, G. Rege Cambrin

M.G. Della Porta

How I treat high risk MDS

S. Amadori

How I treat high risk AML